Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - November 2025

Cencora executive Heather Zenk discusses how innovations in cold chain, data visibility, and sustainability strategies are transforming the drug delivery process.

Building Resilient, Sustainable Pharma Supply Chains

From patent cliffs and government price controls, to self-pay models and staff-model HMOs, a look at the forces that could deflate the bubble—and those factors likely to keep it afloat a while longer.

Popping the Gross-to-Net Bubble, Part VI: The Future of Pharmaceutical Pricing

Advice for pharma distributors and dispensers on what they should do now in order to solidify a secure supply chain.

DSCSA Compliance: Milestones, More Deadlines—and the Road Ahead

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

The new 700,000-square-foot Holly Springs site—part of Roche’s $50 billion US investment plan—will focus on metabolic and obesity treatments, create 400 jobs, and strengthen domestic biopharma manufacturing amid shifting tariff and drug pricing policies.

Genentech Breaks Ground on $700M North Carolina Manufacturing Facility

Podcasts

This episode of Pharma Pulse covers FDA findings of contamination and safety lapses at Novo’s Bloomington manufacturing plant, the rise of off-label GLP-1 prescribing and its equity challenges, and AbbVie’s acquisition of bretisilocin to advance treatments for major depressive disorder.

Pharma Pulse: Novo Nordisk Plant Faces FDA Scrutiny, Off-Label GLP-1 Use Grows, and AbbVie Expands Psychiatry Pipeline

An FDA Form 483 cited unaddressed contamination, pest infestations, and equipment failures at manufacturer’s Bloomington, IN facility, which was acquired in the Catalent buyout. 

Novo Nordisk’s Indiana Plant Flagged by FDA for Contamination and Safety Lapses

Addressing the most common concerns surrounding the legislation intended to establish interoperability within the pharma supply chain. 

Pharma Pulse: CVS Caremark Faces $290M Penalty, Small Practices Miss HIPAA Standards, and Pharmacists Underreport Adverse Drug Reactions

Videos

In the ninth part of this roundtable discussion, industry experts discuss how the pharma supply chain is evolving into an integrated business planning function, highlighting the need for diverse skill sets, digital dexterity, and AI-enabled capabilities to prepare Gen Z and future leaders for patient-centric problem solving.

Peer Exchange: Building the Next-Generation Supply Chain Talent Pipeline (Episode 9)

A federal judge tripled damages against the pharmacy benefits manager after finding it encouraged inflated Medicare drug claims and underpaid pharmacies.

CVS Caremark Ordered to Pay $290 Million in False Claims Act Whistleblower Case

Ron Lanton, partner, Lanton Law, explains that declining public trust and political support for vaccines could force pharmaceutical companies to rethink regulatory strategies and investment priorities in biologics and vaccine development.

Pharma Regulatory Strategies Could Shift as Vaccine Support Declines

This episode of Pharma Pulse covers the White House–EU agreement on pharmaceutical tariffs, Johnson & Johnson’s $2 billion expansion of its North Carolina manufacturing site, and a new federal rule requiring e-prescribing and prior authorization tools in certified EHR systems.

Pharma Pulse: Pharma Tariffs Take Shape, J&J Invests $2 Billion in US Manufacturing, and New EHR Rule Targets Prior Authorization

The new framework, set to take effect Sept. 1, limits tariffs on pharmaceutical imports to 15% but follows months of shifting proposals, including threats of tariffs as high as 250%.

Featured Content

Pharmaceutical Commerce - November 2025

Building Resilient, Sustainable Pharma Supply Chains

Popping the Gross-to-Net Bubble, Part VI: The Future of Pharmaceutical Pricing

DSCSA Compliance: Milestones, More Deadlines—and the Road Ahead